Presentations , November 03-04 2023

Welcome and Introduction, Ryan Fitzpatrick, Joana Torres & Millie Long

Session I: Optimizing Biologic Therapies in IBD

Moderator: Millie Long & Paula Ministro

Joana Torres

Anti-TNF therapy in IBD (including biosimilars)

Joana Torres, Hospital Beatriz Ângelo & Hospital da Luz, Portugal


Anti-integrin therapy in IBD

Paula Ministro, Tondela-Viseu Hospital Center, Viseu, Portugall

Triana Lobaton

IL-23 therapies in IBD

Triana Lobaton, Ghent University Hospital, Ghent, Belgium

Panel Discussion

Session II: Focus on small molecules in IBD

Moderator: Joana Torres 

Naila Arebi

Conventional immunomodulator therapy in IBD – still a role in the armamentarium?

Naila Arebi, St. Mark’s Hospital, Harrow, Middlesex, UK

Severine Vermeire

JAK Inhibitors in IBD: Does selectivity matter?

Séverine Vermeire, Leuven, Belgium

Britta Siegmund

S1P Inhibitors in IBD – how do they work and how to use them?

Britta Siegmund, Universitätsmedizin Berlin, Berlin, Germany

Panel Discussion

Independent Expert Discussion supported by Pfizer

Session III: Women’s health in IBD

Moderator: Séverine Vermeire 

Mette Julsgaard

Pregnancy and IBD

Mette Julsgaard, Aarhus University Hospital, Aarhus, Denmark

Sophie Restellini

Post Delivery: Implications for Mum and Baby

Sophie Restellini, Hôpital de La Tour, Switzerland

Panel Discussion

Session IV: Medical and surgical management of IBD

Moderators: Millie Long & Joana Torres 


Non-invasive monitoring of IBD

Federica Furfaro, IRCCS San Raffaele Hospital

Ana Guttierrez

Treat to Target in IBD – too much or too little?

Ana Guttierrez, Hospital General Universitario de Alicante

Susana Ourô

Surgical Management of the female IBD patient

Susana Ourô, Hospital Beatriz Ângelo & Hospital da Luz, Portugal

Panel discussion & Take-home points from day 1, Millie Long & Joana Torres

Session V: Lifespan of IBD

Moderator: Marla Dubinsky 

Britta Siegmund

Successful Mentorship: A Guide for Mentees and Mentors,

Britta Siegmund, Universitätsmedizin Berlin, Berlin, Germany

Marla C. Dubinsky,

A Pathway to Leadership for Women in GI: Lessons Learned

Marla C. Dubinsky, Icahn School of Medicine Mount Sinai New York

Severine Vermeire

Recognition of a Global Leader in IBD

Séverine Vermeire, Leuven, Belgium

Panel Discussion

Session VI: Positioning of Therapies in IBD

Moderator: Joana Torres 

Charlotte Hedin

Disease location and Severity: Considerations for Positioning of Therapies

Charlotte Hedin, Karolinska University Hospital in Stockholm, Sweden

Millie Long

Safety Considerations for Positioning of Therapies

Millie Long, University of North Carolina,Chapel Hill, North Carolina, USA

Millie Long

Management of Pouchitis in 2023: From Antibiotics to Biologics,

Millie Long University of North Carolina,Chapel Hill, North Carolina, USA

Panel Discussion

Independent Expert Discussion supported by Celltrion

Session VII: Lifespan of IBD

Moderators: Marla C. Dubinsky

Lissy de Ridder

Considerations for the Management of Pediatric IBD

Lissy de Ridder, The Erasmus MC Sophia Children’s Hospital, Rotterdam, The Netherlands

Joana Roseira

Sexuality in the IBD patient

Joana Roseira, Centro Hospitalar do Algarve, Portugal

Daniela Pugliese

Considerations for Management of IBD in Older Individuals

Daniela Pugliese, CEMAD - IBD UNIT Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy

Panel Discussion

Marla C. Dubinsky, MD

Icahn School of Medicine Mount Sinai New York

Marla C. Dubinsky, MD, is a Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Dubinsky received her medical degree from Queen’s University, Canada. She completed her pediatric residency at Alberta Children’s Hospital, Calgary, Canada, and her clinical fellowship in gastroenterology and nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She completed her research fellowship in IBD at Cedars-Sinai Medical Center in Los Angeles, CA, where she served as the Director of the Pediatric IBD Center before going to Mount Sinai as the Chief of Pediatric Gastroenterology and Nutrition at the Mount Sinai Kravis Children’s Hospital and Co-Director of the Susan and Leonard Feinstein IBD Clinical Center. Dr. Dubinsky is also the Co-Director of the IBD Preconception and Pregnancy Planning Clinic at Mount Sinai. She is the Co-Founder of Mi-Test Health, and Cornerstones Health which is a non-profit organization dedicated to enhancing and transforming communication between health care providers, patients, and industry partners through creative, comprehensive, and expert-based educational program. She is also the Co-Founder of Trellus Health, a resilience driven connected health solution for chronic conditions-leading with IBD.
Dr. Dubinsky has been engaged in IBD clinical and translational research for over two decades. Her primary research focuses on developing predictive models and web-based decision support tools that integrate clinical and biomarkers to predict the natural history of IBD and response to therapy. She has a keen interest in personalized medicine in IBD and her research uncovers predictors of rapid disease progression with the goal of preventing complications by altering treatment plans. Dr. Dubinsky is the principal investigator of multiple large longitudinal cohorts including the Road to Prevention Multiplex Family Program at Mount Sinai with over 700 enrolled participants with a goal of using multi-omic data to predict the development of IBD in unaffected family members and co-investigator of the Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn’s Disease (RISK) study and senior author on the manuscript presenting a model to predict the natural history of pediatric Crohn’s disease. Dr. Dubinsky is very committed to women’s reproductive health in IBD and in addition to her research in this field she is the Co-founder of WECARE in IBD, an organization dedicated to the health of women with IBD. She has lectured widely, both nationally and internationally, and has published in more than 275 peer-reviewed journals, including Gastroenterology, Lancet, JAMA, The Journal of Pediatric Gastroenterology and Nutrition, The journal of Crohn’s and Colitis, Inflammatory Bowel Diseases, and the American Journal of Gastroenterology.
In 2022, Dr. Dubinsky received the Sherman Prize for Excellence in Crohn’s and Colitis.

Ana Guttierrez, MD

Hospital General Universitario de Alicante

 Family Name:  Gutiérrez Casbas
 First name:  Ana
 Date and place of Birth: Madrid, 12 of August 1968
 Nationality: Spanish

 Pre-grade studies:

  • 1986-1992: Medicine School, Miguel Hernandez University, Elche, Spain

 Post-grade studies:

  • 1993-1996 Gastroenterology and Hepatology Residency. Hospital General Universitario de Alicante.
  • 1997 PhD Degree in Medicine (cum laude) at Miguel Hernández University Elche, Spain in the Prognostic value of fibrinolytic tests for hospital outcome in patients with acute upper gastrointestinal hemorrhage. 

Professional Experience:

  • 1997-2003: Gastroenterologist at Hospital General Universitario de Elche
  • 2003-2019: Gastroenterologist at Hospital General Universitario de Alicante.
  • From 2020: Head of Gastroenterology Section at Hospital General Universitario de Alicante.
  • From 2006: Head of IBD Unit of Hospital General Universitario de Alicante


Scientific Organisation Membership:

  • Colegio de Médicos de Alicante
  • Sociedad Valenciana de Patología Digestiva.
  • Grupo Español de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Vice president of GETECCU and Teaching Area Coordinator
  • Asociación Española de Gastroenterología, (Spain Association of Gastroenterology)(AEG)
  • ECCO (European Crohn and Colitis Organization)